Business
MangoRx Completes Migration to DEA-Approved Telemedicine Platform, Accelerating Timeline of Oral Dissolvable GLP-1 Weight Loss Treatments Featuring Semaglutide and Tirzepatide
Dallas, Texas, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing,
About this update from Mangoceuticals, Inc.
[{"type":"text","content":"Dallas, Texas, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and wellness products in the areas of erectile dysfunction (ED), hair growth, weight loss, and hormone replacement therapies, proudly announces the successful migration to its newly developed DEA-approved telemedicine operating system. This milestone marks a significant advancement in MangoRx’s capabilities, reinforcing its commitment to innovation and superior patient care. The new operating system, authorized by the DEA and integrated with Surescripts, allows MangoRx’s third-party doctor network to prescribe and offer controlled substances, including Prime by MangoRx, powered by Kyzatrex, an Oral Testosterone Replacement Therapy (TRT), as well as other hormone replacement therapies. This approval not only distinguishes MangoRx in the Direct-to-Consumer (DTC) telemedicine space but also validates the Company’s cutting-edge technology and regulatory compliance. Crucially, this advanced system has accelerated the Company’s ability to introduce new product lines, including the highly anticipated compounded weight loss products, Slim and Trim, featuring Semaglutide and Tirzepatide in an oral dissolvable tablet. The Company anticipates making these products available to patients before the end of the third quarter, capitalizing on the significant demand for GLP-1 weight loss treatments and promising substantial revenue growth for MangoRx. The enhanced capabilities of the new operating system will enable a swift response to market needs, allowing MangoRx to launch new products and treatments much faster than previously anticipated, solidifying the Company’s competitive edge. Amanda Hammer, COO of MangoRx, underscores the system’s transformative impact: “The migration to our DEA-approved operating system marks a pivotal achievement for MangoRx. This advanced system empowers us to offer a broader range of products and respond swiftly to market demands. Our commitment to regulatory compliance and innovation ensures that we deliver exceptional value to our patients and stakeholders. We’re excited about the growth opportunities this system brings and look forward to revolutionizing patient care in the telemedicine industry.” In conjunction with ...